{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:20:54Z","timestamp":1786116054668,"version":"build-2736575974"},"reference-count":80,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,3,28]]},"DOI":"10.1080\/14796694.2026.2640228","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:47:11Z","timestamp":1773766031000},"page":"919-931","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Zolbetuximab for gastroesophageal adenocarcinoma: drug review and lessons from the frontlines"],"prefix":"10.1080","volume":"22","author":[{"given":"Jane E.","family":"Rogers","sequence":"first","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M.","family":"Covert","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leung","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Aune","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Esmaily-Fard","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiba","family":"Mathew","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Sobocinski","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[{"name":"U.T. MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"National Comprehensive Cancer Network. Gastric Cancer. Version 3. 2025 [cited 2025 Nov 18]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"},{"key":"e_1_3_5_4_1","unstructured":"National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. Version 4. 2025 [cited 2025 Nov 18]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.40"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08126-6"},{"key":"e_1_3_5_7_1","unstructured":"National Cancer Institute Surveillance. Epidemiology and end results program. Cancer stat facts: stomach cancer. [cited 2025 Nov 18]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36462-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102175"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_5_12_1","unstructured":"U.S. Food and Drug Administration. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. [cited 2025 Nov 19]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68411-w"},{"key":"e_1_3_5_16_1","unstructured":"RemeGen Co. Ltd. A study of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors. ClinicalTrials.gov. NLM Identifier: NCT05205850. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05205850"},{"key":"e_1_3_5_17_1","unstructured":"RemeGen Co. Ltd. A study of RC118 plus toripalimab\/ RC148 in patients with locally advanced unresectable or metastatic solid tumors. ClinicalTrials.gov. NLM Identifier: NCT06038396. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06038396"},{"key":"e_1_3_5_18_1","unstructured":"Hangzhou Sumgen Biotech Co. Ltd. SG1906 for CLDN18.2-positive solid tumors (CSG-1906\u2013101). ClinicalTrials.gov. NLM Identifier: NCT05857332. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05857332"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205431"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071120"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4038"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251344804"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104000"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100210"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217362"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1596460"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1051497"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21338"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102888"},{"key":"e_1_3_5_30_1","first-page":"1","article-title":"The prognostic role of claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma. A systematic literature review","volume":"9","author":"Fassan M","year":"2025","unstructured":"Fassan M, Chau I, Dasghaib H, et al. The prognostic role of claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma. A systematic literature review. ESMO Gastrointestinal Oncol. 2025;9(C):1\u201317.","journal-title":"ESMO Gastrointestinal Oncol"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2370332"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2474122"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00120-3"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13954"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-209268"},{"key":"e_1_3_5_36_1","unstructured":"Innovent Biologics (Suzhou) Co. Ltd. A multicenter study of IBI343 monotherapy versus placebo in subjects with Previously treated Claudin (CLDN) 18.2-positive pancreatic Cancer(G-HOPE-002). ClinicalTrials.gov. NLM Identifier: NCT07066098. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07066098"},{"key":"e_1_3_5_37_1","unstructured":"Suzhou Transcenta Therapeutics Co. Ltd. Combination of TST001 Nivolumab and chemotherapy as first-line therapy in advanced or metastatic GC\/GEJ adenocarcinoma. ClinicalTrials.gov. NLM Identifier: NCT06093425. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06093425"},{"key":"e_1_3_5_38_1","unstructured":"AskGene Pharma Inc. ASKB589 in combination with CAPOX and PD-1 inhibitor in patients with advanced or metastatic GC\/GEJ adenocarcinoma. ClinicalTrials.gov. NLM Identifier: NCT06206733. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06206733"},{"key":"e_1_3_5_39_1","unstructured":"FutureGen Biopharmaceutical (Beijing) Co. Ltd. M108 plus CAPOX versus placebo plus CAPOX as first-line treatment for claudin (CLDN) 18.2-positive HER2-negative PD-L1 CPS<5 locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. ClinicalTrials.gov. NLM Identifier: NCT06177041.Available from: https:\/\/clinicaltrials.gov\/study\/NCT06177041"},{"key":"e_1_3_5_40_1","unstructured":"CARsgen Therapeutics Co. Ltd. Clinical trial to evaluate AB011 injection in patients with CLDN18.2-positive advanced solid tumors. ClinicalTrials.gov. NLM Identifier: NCT04400383.Available from: https:\/\/clinicaltrials.gov\/study\/NCT04400383"},{"key":"e_1_3_5_41_1","unstructured":"Zhejiang Doer Biologics Co. Ltd. A trial to evaluate the safety tolerability pharmacokinetics and preliminary efficacy of DR30303 in patients with advanced solid tumors. ClinicalTrials.gov.NLM Identifier: NCT05639153. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05639153"},{"key":"e_1_3_5_42_1","unstructured":"NovaRock Biotherapeutics Ltd. Evaluation of the safety and efficacy of NBL-015 in patients with advanced solid tumors. ClinicalTrials.gov. NLM Identifier: NCT05153096. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05153096"},{"key":"e_1_3_5_43_1","unstructured":"TORL Biotherapeutics LLC. First in human study of TORL-2\u2013307-MAB in participants with advanced cancer. ClinicalTrials.gov. NLM Identifier: NCT05159440.Available from: https:\/\/clinicaltrials.gov\/study\/NCT05159440"},{"key":"e_1_3_5_44_1","unstructured":"Zai Biopharmaceutical (Suzhou) Co. Ltd. A study of ZL-1211 in patients with advanced solid tumor. ClinicalTrials.gov. NLM Identifier: NCT05065710. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05065710"},{"key":"e_1_3_5_45_1","unstructured":"LaNova Medicines Zhejiang Co. Ltd. LM-302 for the treatment of subjects with Claudin18.2-positive gastric and gastroesophageal junction adenocarcinoma. ClinicalTrials.gov. NLM Identifier: NCT06351020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06351020"},{"key":"e_1_3_5_46_1","unstructured":"AstraZeneca. AZD0901 compared with Investigator\u2019s choice of therapy in participants with second- or later-line advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2. ClinicalTrials.gov. NLM Identifier: NCT06346392.Available from: https:\/\/clinicaltrials.gov\/study\/NCT06346392"},{"key":"e_1_3_5_47_1","unstructured":"Antengene Biologics Limited. A study of ATG-022 in patients with advanced\/metastatic solid tumors (CLINCH). ClinicalTrials.gov.NLM Identifier: NCT05718895. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05718895"},{"key":"e_1_3_5_48_1","unstructured":"Shanghai Hengrui Pharmaceutical Co. Ltd. SHR-A1904 combinations in CLDN18.2-positive advanced solid tumor. ClinicalTrials.gov.NLM Identifier: NCT06350006.Available from: https:\/\/clinicaltrials.gov\/study\/NCT06350006"},{"key":"e_1_3_5_49_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. A study of SKB315 in patients with advanced solid tumors. ClinicalTrials.gov. NLM Identifier: NCT05367635.Available from: https:\/\/clinicaltrials.gov\/study\/NCT05367635"},{"key":"e_1_3_5_50_1","unstructured":"TORL Biotherapeutics LLC. First in human study of TORL-2\u2013307-ADC in participants with advanced cancer. ClinicalTrials.gov. NLM Identifier: NCT05156866.Available from: https:\/\/clinicaltrials.gov\/study\/NCT05156866"},{"key":"e_1_3_5_51_1","unstructured":"I-Mab Biopharma US Limited. Study of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors. ClinicalTrials.gov. NLM Identifier: NCT04900818.Available from: https:\/\/clinicaltrials.gov\/study\/NCT04900818"},{"key":"e_1_3_5_52_1","unstructured":"Innovent Biologics (Suzhou) Co. Ltd. Safety and efficacy of IBI389 single agent and in combination with sintilimab in patients with advanced malignancies. ClinicalTrials.gov. NLM Identifier: NCT05164458. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05164458"},{"key":"e_1_3_5_53_1","unstructured":"AstraZeneca. Study of AZD5863 in adult participants with advanced or metastatic solid tumors. ClinicalTrials.gov. NLM Identifier: NCT06005493. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06005493"},{"key":"e_1_3_5_54_1","unstructured":"Astellas Pharma Global Development Inc. A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer gastroesophageal junction cancer or pancreatic cancer. ClinicalTrials.gov. NLM Identifier: NCT05365581. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05365581"},{"key":"e_1_3_5_55_1","unstructured":"Phanes Therapeutics. Spevatamig (PT886) as monotherapy or in combination with chemo and\/or ICI for the treatment of patients with advanced gastric gastroesophageal junction pancreatic ductal or biliary tract carcinomas (the TWINPEAK study). ClinicalTrials.gov. NLM Identifier: NCT05482893. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05482893"},{"key":"e_1_3_5_56_1","unstructured":"Peking University. Postoperative adjuvant therapy for CT041 gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma patients (CT041-CG4010). ClinicalTrials.gov. NLM Identifier: NCT06857786. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06857786"},{"key":"e_1_3_5_57_1","unstructured":"Legend Biotech USA Inc. Claudin 18.2-targeted chimeric antigen receptor T-cells in subjects with unresectable locally advanced or metastatic gastric gastroesophageal junction (GEJ) esophageal or pancreatic adenocarcinoma. ClinicalTrials.gov. NLM Identifier: NCT05539430. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05539430"},{"key":"e_1_3_5_58_1","unstructured":"Market Research Report. Claudin 18.2 targeted therapy market by product type (Monoclonal antibodies antibody-drug conjugates CAR-T cell therapies); by indication (Gastric and gastroesophageal junction cancer pancreatic cancer lung adenocarcinoma Others); by therapeutic modality (antibody-based therapy bispecific antibody constructs cell therapy small molecule Inhibitors); by end user (hospitals & oncology centers specialty clinics Academic & Research institutions diagnostic Laboratories); by geography segment revenue estimation forecast 2025\u20132030. 2025. Available from: https:\/\/www.strategicmarketresearch.com\/market-report\/claudin-18-2-targeted-therapy-market"},{"key":"e_1_3_5_59_1","unstructured":"DelvenSight Business Research LLP. Claudin 18.2-directed oncology Therapeutics\u2013A fast-growing market with blockbuster potential | DelveInsight. Available from: https:\/\/www.prnewswire.com\/news-releases\/claudin-18-2-directed-oncology-therapeuticsa-fast-growing-market-with-blockbuster-potential\u2013delveinsight-302511738.html#:~:text=As%20per%20DelveInsight\u2019s%20analysis%2C%20the market%20in%20the%20coming%20years"},{"key":"e_1_3_5_60_1","unstructured":"Astellas Pharma Global Development Inc. A study of zolbetuximab with chemotherapy in adults with pancreatic cancer. ClinicalTrials.gov. NLM Identifier: NCT06396091. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06396091"},{"key":"e_1_3_5_61_1","unstructured":"Astellas Pharma Global Development Inc. A study of zolbetuximab together with pembrolizumab and chemotherapy in adults with gastric cancer (LUCERNA). ClinicalTrials.gov. NLM Identifier: NCT06901531. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06901531"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70280"},{"key":"e_1_3_5_63_1","unstructured":"Vyloy (Zolbetuximab) package insert. Astellas Pharma US Inc. 2025."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.316"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2024.04.004"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0204"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz199"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.007"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e15079"},{"key":"e_1_3_5_71_1","unstructured":"Hematology Oncology Pharmacy Association. Dose Rounding of biologic and cytotoxic anticancer agents: a position statement of the Hematology\/oncology Pharmacy association. 2017 [cited 2025 Nov 21]. Available from: https:\/\/www.hoparx.org\/documents\/102\/Dose-Rounding-Position-Paper-2017-10-23.pdf"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100131"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-1"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2024.08.005"},{"key":"e_1_3_5_76_1","unstructured":"National Comprehensive cancer Network. Antiemesis. Version 2. 2025. Available from: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01997"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100128"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121996"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1258347"},{"key":"e_1_3_5_81_1","unstructured":"Astellas answers. Where has zolbetuximab received regulatory approval? Available from: https:\/\/www.astellasanswers.com\/us\/zolbetuximab\/zolbetuximab-regulatory-approval"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103663"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2640228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2640228","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2640228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:40:33Z","timestamp":1786002033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2640228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,3,28]]}},"alternative-id":["10.1080\/14796694.2026.2640228"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2640228","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}